Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings

Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita
April 2014
PLoS ONE;Apr2014, Vol. 9 Issue 4, p1
Academic Journal
Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D levels, but these studies have been done in North American and European populations. Methods: Using a prospective cohort study design nested in a multinational clinical trial, we examined the effect of three combination antiretroviral (cART) regimens on serum vitamin D levels in 270 cART-naïve, HIV-infected adults in nine diverse countries, (Brazil, Haiti, Peru, Thailand, India, Malawi, South Africa, Zimbabwe and the United States). We evaluated the change between baseline serum vitamin D levels and vitamin D levels 24 and 48 weeks after cART initiation. Results: Serum vitamin D levels decreased significantly from baseline to 24 weeks among those randomized to efavirenz/lamivudine/zidovudine (mean change: −7.94 [95% Confidence Interval (CI) −10.42, −5.54] ng/ml) and efavirenz/emtricitabine/tenofovir-DF (mean change: −6.66 [95% CI −9.40, −3.92] ng/ml) when compared to those randomized to atazanavir/emtricitabine/didanosine-EC (mean change: −2.29 [95% CI –4.83, 0.25] ng/ml). Vitamin D levels did not change significantly between week 24 and 48. Other factors that significantly affected serum vitamin D change included country (p<0.001), season (p<0.001) and baseline vitamin D level (p<0.001). Conclusion: Efavirenz-containing cART regimens adversely affected vitamin D levels in patients from economically, geographically and racially diverse resource-limited settings. This effect was most pronounced early after cART initiation. Research is needed to define the role of Vitamin D supplementation in HIV care.


Related Articles

  • Tenofovir/Emtricitabine/Efavirenz Plus Rosuvastatin Decrease Serum Levels of Inflammatory Markers More Than Antiretroviral Drugs Alone in Antiretroviral Therapy-Naive HIV-Infected Patients. Calza, Leonardo; Vanino, Elisa; Salvadori, Caterina; Manfredi, Roberto; Colangeli, Vincenzo; Cascavilla, Alessandra; Di Bari, Maria Assunta; Motta, Roberto; Viale, Pierluigi // HIV Clinical Trials;Jan/Feb2014, Vol. 15 Issue 1, p1 

    Objectives: Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. Design: To assess the anti-inflamatory effects of statins in HIV-infected patients, because...

  • Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. Eric S. Daar, MD; Camlin Tierney, PhD; Margaret A. Fischl, MD; Paul E. Sax, MD; Katie Mollan, MS; Chakra Budhathoki, PhD;; Godfrey, Catherine; Jahed, Nasreen C.; Myers, Laurie; Katzenstein, David; Farajallah, Awny; Rooney, James F.; Pappa, Keith A.; Woodward, William C.; Patterson, Kristine; Bolivar, Hector; Benson, Constance A.; Collier, Ann C. // Annals of Internal Medicine;4/5/2011, Vol. 154 Issue 7, p445 

    Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change or discontinuation of regimen (tolerability) for atazanavir plus ritonavir with...

  • Optimizing Initial Therapy for HIV Infection. Hull, Mark W.; Montaner, Julio S. G. // Journal of Infectious Diseases;10/15/2011, Vol. 204 Issue 8, p1154 

    An introduction is presented in which the author discusses the use of efavirenz and boosted atazanavir in combination with tenofovir/ emtricitabine as initial therapy for treatment against HIV infection.

  • Rilpivirine bested efavirenz combo in HIV.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p40 

    The article discusses research on the safety and effectiveness of efavirenz plus standard therapy in patients with HIV-1 infection, published in "Lancet."

  • Use of Non-Nucleoside Analogues Together with Rifampin in HIV Patients with Tuberculosis. Villar, J.; Sánchez, P.; González, A.; Sorli, L; Montero, M.M.; Guelar, A.; Solé, E.; López, J. L.; Knobel, H. // HIV Clinical Trials;May/Jun2011, Vol. 12 Issue 3, p171 

    Objective: The concomitant use of rifampin (RFP) with efavirenz (EFV) or nevirapine (NVP) is frequent in HIV patients with tuberculosis (TB). The necessity of increasing the dose of EFV remains controversial. The aim of the study was to evaluate the outcome of HIV infection in patients treated...

  • Oxidative stress induced by chronic administration of Efavirenz on the intracranial visual relay centers of adult Wistar rats. Adjene, J. O.; Avbunudiogba, J. A.; Igbigbi, P. S. // Biology & Medicine;Oct-Dec2011, Vol. 3 Issue 5, p16 

    The biochemical effects of chronic administration of efavirenz commonly used as part of highly active antiretroviral therapy (HAART) for the treatment of Human Immunodeficiency Virus (HIV) type-1 on the intracranial visual relay centres (namely superior colliculus and lateral geniculate body) of...

  • Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection. Lyseng-Williamson, Katherine A.; Scott, Lesley J. // Clinical Drug Investigation;2012, Vol. 32 Issue 10, p715 

    The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Evipleraâ„¢ [EU]; Compleraâ„¢ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient...

  • Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). Gallien, Sébastien; Journot, Valérie; Rozenbaum, Willy; Yéni, Patrick; Morlat, Philippe; Poizot-Martin, Isabelle; Reynes, Jacques; Reliquet, Véronique; Leclercq, Pascale; Simon, François; Chêne, Geneviève; Molina, Jean-Michel // Journal of Antimicrobial Chemotherapy (JAC);Jan2011, Vol. 66 Issue 1, p184 

    Background Once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine. Methods The ALIZE ANRS 099 trial enrolled 355 adults with...

  • Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types. Gordon, Lindsay L.; Gharibian, Derenik; Chong, Karen; Chun, Helen // AIDS Patient Care & STDs;Jul2015, Vol. 29 Issue 7, p384 

    Medication adherence is a major determinant of antiretroviral (ARV) treatment success and a significant challenge for HIV-positive patients, yet a well-defined adherence threshold to maintain virologic suppression on current ARV regimens remains unclear. The present study evaluated 1915 Kaiser...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics